Innovent Biologics NDA for IBI311 in thyroid eye disease treatment gets priority review in China
Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that its New Drug Application (NDA) for IBI311, a pioneering treatment for Thyroid Eye Disease ... Read More
Amgen seeks European approval for teprotumumab in thyroid eye disease
Amgen (NASDAQ: AMGN), a global biotechnology leader, has announced its plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ... Read More